Search
Close this search box.

Advances in TomoTherapy®/Radixact® Treatment and QA – Guidelines from TG-306

Since the publication of Task Group 148 in 2010, the TomoTherapy platform has undergone substantial development involving treatment delivery, image guidance, motion management, and treatment planning systems (TPS). New hardware and software capabilities have dramatically changed its delivery and planning characteristics. Task Group 306 was formed to provide guidance on the implementation, management, and quality assurance for these technological advances. In this session, the work of Task Group 306 will be presented. Changes to the TomoTherapy platform since 2010 and the impact on clinical delivery and QA practices, including QA tests and tolerance limits will be presented.

Planning for Multiple Brain Metastases with the CyberKnife® System

Dr. Daniela Schmitt is a medical physicist in the Department of Radiation Oncology at the Heidelberg University Hospital in Germany. Since the commencement of the CyberKnife Program at Heidelberg in 2016 Dr. Schmitt’s focus has been on CyberKnife planning. Prior to joining Heidelberg University Hospital in 2014 Dr. Schmitt worked at the CyberKnife Center in Frankfurt. She obtained her PhD in physics from the University of Heidelberg working at the German Cancer Research Center under the supervision of Prof. Uwe Oelfke in 2014.

TomoTherapy® with VoLO™ & TomoEDGE™: Special Considerations in Treatment Planning

Since its release, the TomoTherapy® platform has noticeably improved in its flexibility and efficiency of treatment planning. Within this newfound flexibility many of the original planning parameters are being reinvestigated in regard to their suitability, robustness, and efficiency of planning. This talk aims to open the discussion of planning on the TomoTherapy platform and help users understand how to efficiently arrive to where they want to be with their clinical dosimetry.

User Resources

Accuray Insights